This group comprises preparations used in the treatment of Parkinsons disease and related conditions, including drug-induced parkinsonism.
The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease. No separate DDDs are established for oral depot formulations.
N04B - Dopaminergic Agents
N04BX - Other Dopaminergic Agents
This group comprises dopaminergic agents which cannot be classified in the preceding groups. The combination of levodopa, decarboxylase inhibitor and COMT inhibitor is classified in N04BA - Dopa and dopa derivatives.
